MedTrace Logo

A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers

NCT02016742 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-03-12

No results posted yet for this study

Summary

The purpose of this study is to characterise the pharmacokinetics, safety and tolerability of RDC5 given as a single dose to healthy volunteers at a number of different dose levels

Conditions

  • Healthy Volunteers

Interventions

DRUG

RDC5

Sponsors & Collaborators

  • Chronos Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Girish Sharma · Simbec Research

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016742 on ClinicalTrials.gov